Quoin Pharmaceuticals, Ltd. — Director's Dealing 2025

Jun 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2025-05-29

Reporting Person: Cooper Joseph Patrick (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-29	Share Option (Right to Buy)	$9.07	A	7760	Acquired	2035-05-29	ADS (7760)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.